CytoPherx, a US-based medical device maker for inflammation-based diseases, has raised $34m in its series C round from a consortium including healthcare provider Kaiser Permanente’s corporate venturing unit.
News provider CB Insights said, apart from Kaiser Permanente Ventures, the other investors in the round were venture capital firms Early Stage Partners, Onset Ventures, Capital Midwest Fund, Emergent Medical Partners, Charter Oak Private Equity, Aphelion Capital, Lurie Investment Fund, Apjohn Ventures and North Coast Technology Investors as well as the Dow Employees Pension Plan.
Founded in 2007, CytoPherx previously raised $4.5m that year and $7.5m in its B round in 2009, according to news provider Xconomy.